Global Post-traumatic Stress Disorder Treatment Market– Drivers
Increasing number of inorganic strategies such as product launches, collaborations, expansion, and partnerships to develop drugs for the treatment of post-traumatic stress disorder is expected to drive the growth of the global post-traumatic stress disorder treatment market over the forecast period.
Increasing number of product launch and collaboration between the key market players in the treatment of PTSD is expected to drive the growth of the global post-traumatic stress disorder treatment market over the forecast period. For instance, on March 30, 2022, Sun Pharmaceutical Industries Ltd., a pharmaceutical company, entered into a patent licensing agreement with H. Lundbeck, a pharmaceutical company, to market and distribute its own version of Vortioxetine (an antidepressant pill) in India under the brand name Vortidiftm. Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in more than 80 countries, including the U.S., Europe, Canada, and Australia.
Increasing number of research and development for the treatment of post-traumatic stress disorder by market players in North America is expected to drive the growth of the global post-traumatic stress disorder treatment market over the forecast period.
Incrasing research and development by the key market players in the treatment of post-traumatic stress disorder are expected to boost the global post-traumatic stress disorder treatment market over the forecast period. For instance, in December 2020, Tonix Pharmaceuticals Holding Corp., a pharmaceutical company, announced positive results from its Phase 3 RECOVERY study1 of TNX-102 SL 5.6 mg, for the treatment of civilian and military-related post-traumatic stress disorder.
Global Post-traumatic Stress Disorder Treatment Market: Restraint
One of the major restraints of the global post-traumatic stress disorder treatment market is lack of awareness and side effects associated with the drugs, such as Sertraline, Paroxetine, and others used in the treatment of post-traumatic stress disorder.
The primary side effects of sertraline include syncope, lightheadedness, diarrhea, nausea, sweating, dizziness, xerostomia, confusion, hallucinations, tremor, somnolence, impotency, fatigue, rhinitis, and female sexual disorder. Also, there is a bleeding risk associated with sertraline, as it may inhibit platelet aggregation. Whereas, the side effects associated with paroxetine include changes in mood, anxiety or behavior, serotonin syndrome or neuroleptic malignant syndrome-like reactions, eye problems, severe allergic reactions, bruising/ bleeding, seizures or convulsions, manic episodes, changes in appetite or weight, low sodium levels, and bone fracture.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients